Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest BPH Stories

2013-02-15 20:21:07

SAN DIEGO, CA and VANCOUVER, BC, Feb. 15, 2013 /PRNewswire/ - Sophiris Bio Inc. (Sophiris, TSX: SHS) ("Sophiris" or the "Company"), a biopharmaceutical company developing a treatment for benign prostatic hyperplasia (BPH or enlarged prostate), announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial U.S. public offering of its common shares on the NASDAQ stock market. The Company has...

2012-11-06 16:27:50

SAN DIEGO, CA and VANCOUVER, BC, Nov. 6, 2012 /PRNewswire/ - Sophiris Bio Inc. (TSX: SHS), a urology company developing a late-stage, highly targeted treatment for benign prostatic hyperplasia (BPH or enlarged prostate), today announced that Randall E. Woods, President and Chief Executive Officer, will present an overview of the Company at the Lazard Capital Markets 9(th) Annual Healthcare Conference in New York. Mr. Woods' presentation will take place at 4:00 p.m. EST on Tuesday,...

2012-11-02 15:23:17

NEW YORK, Nov. 2, 2012 /PRNewswire/ -- Dr. David Samadi, top robotic prostatectomy SMART surgeon, knows a thing or two about prostates. In fact, he's successfully removed more than 4,000 of them from men with prostate cancer. But cancer isn't the only prostate problem out there. Benign prostatic hyperplasia (BPH), or hypertrophy, is an overgrowth of prostate cells causing an enlarged prostate gland. Dr. Samadi is also a leader in BPH surgery, performing significantly more TURP and...

Saw Palmetto Safe For Men
2012-10-20 08:31:36

April Flowers for redOrbit.com — Your Universe Online A new study published this week in the Journal of Urology finds the popular supplement saw palmetto may be safe for men with urinary symptoms. The study does not, however, make any claims about the efficacy of the supplement. Some men take saw palmetto, which is a fruit extract, to alleviate the symptoms of an enlarged prostate, including difficulty urinating, urine leakage, and repeated nighttime trips to the restroom. Saw...

2012-10-09 07:27:06

Single administration of PRX302 as a short outpatient procedure provided sustained benefit over 12 months SAN DIEGO, CA and VANCOUVER, Oct. 9, 2012 /PRNewswire/ - Sophiris Bio Inc. (TSX: SHS) today released top line data from the 12 month follow up of patients receiving PRX302 for the treatment of benign prostatic hyperplasia (BPH, or enlarged prostate) in a Phase 2b study (TRIUMPH). PRX302 produced a clinically significant improvement in the subjective symptom score (International...

2012-10-02 10:28:45

SAN DIEGO, CA and VANCOUVER, Oct. 2, 2012 /PRNewswire/ - Sophiris Bio Inc. (TSX: SHS), a urology company developing a late-stage, highly targeted treatment for benign prostatic hyperplasia (BPH or enlarged prostate), today announced that Randall E. Woods, President and Chief Executive Officer, will present at the 11(th) Annual BIO Investor Forum in San Francisco. Mr. Woods' presentation will take place at 4:00 p.m. PDT on Tuesday, October 9, 2012. A live webcast of the presentation...

2012-09-21 02:23:47

INDIANAPOLIS, Sept. 21, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of Cialis® (tadalafil) tablets 5 mg for once a day use for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). The CHMP's opinion is now referred to the European Commission, which has the authority to approve...

2012-08-31 02:24:41

SAN DIEGO, CA and VANCOUVER, Aug. 31, 2012 /PRNewswire/ - Sophiris Bio Inc. (TSX: SHS) today announced data from its transrectal safety study, in which PRX302, the company's drug candidate for the treatment of Benign Prostatic Hyperplasia (BPH or enlarged prostate), was well tolerated through three months following a transrectal injection. The results support the use of a transrectal ultrasound (TRUS) guided injection for the delivery of PRX302 directly into the prostate. This route...

2012-08-21 02:27:26

MINNETONKA, Minn., Aug. 21, 2012 /PRNewswire/ -- American Medical Systems (AMS), an Endo Health Solutions (Nasdaq: ENDP) company and a leading provider of devices and therapies for male and female pelvic health, today introduced the new 650kJ MoXy(®) fiber for its class-leading GreenLight XPS(®) system for photoselective vaporization of the prostate. Providing more than 50 percent more energy than the previous fiber for the same price, the new MoXy fiber will enable physicians to...

2012-05-19 23:01:11

HoLEP attains rapid adoption and acceptance as the Proven Procedure for Treating BPH Yokneam, Israel (PRWEB) May 19, 2012 Lumenis Ltd., the world's largest medical laser company developing, manufacturing and distributing a broad range of medical lasers and sophisticated energy delivery equipment for surgical, aesthetic and ophthalmic applications, announces that it will feature distinguished speakers from around the globe who will share their insights into the latest advances in surgical...